IDEXX Laboratories (Nasdaq: IDXX ) reported earnings on April 20. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), IDEXX Laboratories beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded significantly.
Margins grew across the board.
IDEXX Laboratories reported revenue of $322.7 million. The 10 analysts polled by S&P Capital IQ looked for revenue of $314.7 million on the same basis. GAAP reported sales were 10% higher than the prior-year quarter's $292.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.72. The 11 earnings estimates compiled by S&P Capital IQ predicted $0.71 per share. GAAP EPS of $0.72 for Q1 were 16% higher than the prior-year quarter's $0.62 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 54.2%, 130 basis points better than the prior-year quarter. Operating margin was 18.7%, 40 basis points better than the prior-year quarter. Net margin was 12.6%, 10 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $340.1 million. On the bottom line, the average EPS estimate is $0.90.
Next year's average estimate for revenue is $1.31 billion. The average EPS estimate is $3.08.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 216 members out of 227 rating the stock outperform, and 11 members rating it underperform. Among 71 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 70 give IDEXX Laboratories a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on IDEXX Laboratories is hold, with an average price target of $85.94.
The health-care investing landscape is littered with also-rans and a few major winners. Is IDEXX Laboratories performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.